Profund Advisors LLC Buys 29,314 Shares of Definium Therapeutics, Inc. $DFTX

Profund Advisors LLC raised its stake in Definium Therapeutics, Inc. (NASDAQ:DFTX) by 216.0% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 42,885 shares of the company’s stock after buying an additional 29,314 shares during the period. Profund Advisors LLC’s holdings in Definium Therapeutics were worth $1,632,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in DFTX. GAMMA Investing LLC increased its position in shares of Definium Therapeutics by 28.3% during the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock worth $59,000 after acquiring an additional 343 shares during the period. Heritage Wealth Management Inc. CA boosted its holdings in shares of Definium Therapeutics by 3.3% in the third quarter. Heritage Wealth Management Inc. CA now owns 12,400 shares of the company’s stock valued at $472,000 after purchasing an additional 400 shares during the period. TD Waterhouse Canada Inc. boosted its holdings in shares of Definium Therapeutics by 1.2% in the third quarter. TD Waterhouse Canada Inc. now owns 37,147 shares of the company’s stock valued at $1,396,000 after purchasing an additional 453 shares during the period. Kingswood Wealth Advisors LLC boosted its holdings in shares of Definium Therapeutics by 2.0% in the third quarter. Kingswood Wealth Advisors LLC now owns 32,065 shares of the company’s stock valued at $1,220,000 after purchasing an additional 621 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. grew its stake in Definium Therapeutics by 2,928.0% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company’s stock worth $29,000 after purchasing an additional 732 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Piper Sandler restated an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a report on Monday, October 19th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Definium Therapeutics in a research report on Monday, September 14th. Canaccord Genuity Group set a $78.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $66.00 price objective on shares of Definium Therapeutics in a report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Insider Buying and Selling

In other news, CEO Robert Barrow sold 31,550 shares of the business’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the completion of the transaction, the chief executive officer directly owned 2,213,090 shares of the company’s stock, valued at approximately $80,932,701.30. The trade was a 1.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew Wiley sold 3,097 shares of the company’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $113,257.29. Following the sale, the insider owned 359,036 shares of the company’s stock, valued at $13,129,946.52. This trade represents a 0.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is owned by insiders.

Definium Therapeutics Stock Performance

Shares of DFTX stock opened at $32.47 on Tuesday. The firm has a market cap of $4.36 billion, a price-to-earnings ratio of -9.47 and a beta of 2.19. The company’s 50 day moving average is $37.52 and its 200 day moving average is $29.60. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics, Inc. has a 52-week low of $10.46 and a 52-week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, sell-side analysts anticipate that Definium Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.